株探米国株
英語
エドガーで原本を確認する
6-K 1 ea0231337-6k_sapiens.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2025

 

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrants name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800 Israel

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 


 

CONTENTS

 

Exhibit   Title of Exhibit
99.1   Sapiens Reports Fourth Quarter 2024 Financial Results

 

1


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Sapiens International Corporation N.V.
   
Date: February 18, 2025 By: /s/ Roni Giladi
    Name:  Roni Giladi
    Title: Chief Financial Officer

 

2


 

Exhibit Index

 

The following exhibit is furnished as part of this Form 6-K:

 

Exhibit   Description
99.1   Sapiens Reports Fourth Quarter 2024 Financial Results

 

 

3

 

 

EX-99.1 2 ea023133701ex99-1_sapiens.htm SAPIENS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

 Exhibit 99.1

 

 

 

Sapiens Reports Fourth Quarter 2024 Financial Results

 

Rochelle Park, NJ, February 18, 2025 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the fourth quarter ended December 31, 2024.

 

Summary Results for Fourth Quarter 2024 (USD in millions, except per share data)

 

    GAAP           Non-GAAP        
    Q4 2024     Q4 2023     % Change     Q4 2024     Q4 2023     % Change  
Revenue   $ 134.3     $ 130.9       2.6 %   $ 134.3     $ 130.9       2.6 %
Gross Profit   $ 60.1     $ 55.9       7.5 %   $ 62.7     $ 59.4       5.6 %
Gross Margin     44.8 %     42.8 %      200 bps       46.7 %     45.4 %     130 bps  
Operating Income   $ 21.7     $ 20.1       8.0 %   $ 24.5     $ 24.2       1.3 %
Operating Margin     16.2 %     15.4 %      80 bps       18.2 %     18.4 %     -20 bps  
Net Income (*)   $ 17.9     $ 17.0       5.3 %   $ 20.7     $ 20.1       3.1 %
Diluted EPS   $ 0.32     $ 0.30       6.7 %   $ 0.37     $ 0.36       2.8 %

 

Summary Results for Full Year end 2024 (USD in millions, except per share data)

 

    GAAP         Non-GAAP      
    2024     2023     % Change     2024     2023     % Change  
Revenue   $ 542.4     $ 514.6       5.4 %   $ 542.4     $ 514.8       5.4 %
Gross Profit   $ 238.1     $ 219.6       8.4 %   $ 248.9     $ 233.0       6.8 %
Gross Margin     43.9 %     42.7 %     120 bps       45.9 %     45.3 %     60 bps  
Operating Income   $ 85.8     $ 78.9       8.9 %   $ 98.7     $ 94.1       4.8 %
Operating Margin     15.8 %     15.3 %     50 bps       18.2 %     18.3 %     -10 bps  
Net income (*)   $ 72.2     $ 62.4       15.6 %   $ 83.3     $ 75.0       11.0 %
Diluted EPS   $ 1.29     $ 1.12       15.2 %   $ 1.48     $ 1.35       9.6 %

 

(*) Attributable to Sapiens’ shareholders

 


 

Roni Al-Dor, President and CEO of Sapiens, stated, “In the fourth quarter we achieved $134 million in revenue, a 2.6% year over year increase. This quarter showcased solid execution across our key regions and ongoing growth of our core Life business. For the full year 2024, we delivered a 5.4% increase in revenue, reflecting the signing of deals with new and existing customers. North America led our global performance with a 6.3% year-over-year revenue increase. By leveraging our Microsoft cloud strategy and scalable SaaS platform, we are accelerating our clients’ migration to the cloud.”

 

“Our continued investment in a future-proof, modular, open insurance platform-integrating core capabilities with advanced data analytics and AI-is set to drive further growth. We are well positioned to deepen relationships with existing customers, capture additional market share, and strengthen growth across all regions.”

 

“We are introducing 2025 guidance for non-GAAP revenue in a range of $553 million to $558 million, and non-GAAP operating profit in a range of $98 million to $102 million with operating margin of 18% at the midpoint. On a constant currency basis, our growth rate would be 3.4%, and our operating margin would be 18.7% at the mid-point.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast today, February 18, 2025, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): 1-888-642-5032
International: 972-3-9180644
UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: veidan.activetrail.biz/sapiensq4-2024. A replay of the call will be available one business day following the completion of the event at the same link for 90 days.

 

2


 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, ARR, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

3


 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Annual Recurring Revenue (“ARR”) as the annualized value of our revenue from customer subscriptions, term licenses, maintenance, application maintenance, and cloud solutions, which may not be the same as the timing and amount of revenue recognized. The ARR run rate is equal to the product of (i) the sum of these revenues in our most recently completed fiscal quarter, multiplied by (ii) four.

 

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

4


 

About Sapiens

 

Sapiens International Corporation (NASDAQ and TASE: SPNS) is a global leader in intelligent insurance software solutions. With Sapiens’ robust platform, customer-driven partnerships, and rich ecosystem, insurers are empowered to future-proof their organizations with operational excellence in a rapidly changing marketplace. We help insurers harness the power of AI and advanced automation to support core solutions for property and casualty, workers’ compensation, and life insurance, including reinsurance, financial & compliance, data & analytics, digital, and decision management. Sapiens boasts a longtime global presence, serving over 600 customers in more than 30 countries with its innovative SaaS offerings. Recognized by industry experts and selected for the Microsoft Top 100 Partner program, Sapiens is committed to partnering with our customers for their entire transformation journey and is continuously innovating to ensure their success.

 

Investor and Media Contact

 

Yaffa Cohen-Ifrah

Chief Marketing Officer and Head of Investor Relations, Sapiens

Yaffa.cohen-ifrah@sapiens.com

+1 917-533-4782

 

Investor Contacts

 

Brett Maas
Managing Partner, Hayden IR
+1 646-536-7331
brett@haydenir.com

 

Kimberly Rogers
Managing Director, Hayden IR
+1 541-904-5075
kim@HaydenIR.com

 

 

5


 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

6


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
Revenue     134,305       130,859       542,379       514,584  
Cost of revenue     74,158       74,910       304,272       294,990  
                                 
Gross profit     60,147       55,949       238,107       219,594  
                                 
Operating expenses:                                
Research and development, net     16,523       16,084       66,302       63,475  
Selling, marketing, general and administrative     21,926       19,776       85,956       77,251  
Total operating expenses     38,449       35,860       152,258       140,726  
                                 
Operating income     21,698       20,089       85,849       78,868  
                                 
Financial and other expenses (income), net     (864 )     (560 )     (3,978 )     1,750  
Taxes on income     4,695       3,624       17,507       14,251  
                                 
Net income     17,867       17,025       72,320       62,867  
                                 
Attributable to non-controlling interest     -       52       141       423  
                                 
Net income attributable to Sapiens’ shareholders     17,867       16,973       72,179       62,444  
                                 
Basic earnings per share     0.32       0.30       1.29       1.13  
                                 
Diluted earnings per share     0.32       0.30       1.29       1.12  
                                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     55,887       55,733       55,821       55,372  
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     56,164       55,910       56,154       55,721  

 

7


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
GAAP revenue     134,305       130,859       542,379       514,584  
Valuation adjustment on acquired deferred revenue     -       55       -       220  
Non-GAAP revenue     134,305       130,914       542,379       514,804  
                                 
GAAP gross profit     60,147       55,949       238,107       219,594  
Revenue adjustment     -       55       -       220  
Amortization of capitalized software     1,540       1,501       6,124       5,775  
Amortization of other intangible assets     1,005       1,865       4,635       7,396  
Non-GAAP gross profit     62,692       59,370       248,866       232,985  
                                 
GAAP operating income     21,698       20,089       85,849       78,868  
Gross profit adjustments     2,545       3,421       10,759       13,391  
Capitalization of software development     (1,759 )     (1,543 )     (7,133 )     (6,518 )
Amortization of other intangible assets     1,211       1,169       4,943       4,403  
Stock-based compensation     723       698       2,952       3,658  
Acquisition-related costs (*)     50       318       1,298       339  
Non-GAAP operating income     24,468       24,152       98,668       94,141  
                                 
GAAP net income attributable to Sapiens’ shareholders     17,867       16,973       72,179       62,444  
Operating income adjustments     2,770       4,063       12,819       15,273  
Taxes on income     73       (955 )     (1,735 )     (2,693 )
Non-GAAP net income attributable to Sapiens’ shareholders     20,710       20,081       83,263       75,024  

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as completed or prospective third-party services, such as tax, accounting and legal rendered.

 

8


 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
                         
GAAP operating profit     21,698       20,089       85,849       78,868  
                                 
Non-GAAP adjustments:                                
Valuation adjustment on acquired deferred revenue     -       55       -       220  
Amortization of capitalized software     1,540       1,501       6,124       5,775  
Amortization of other intangible assets     2,216       3,034       9,578       11,799  
Capitalization of software development     (1,759 )     (1,543 )     (7,133 )     (6,518 )
Stock-based compensation     723       698       2,952       3,658  
Compensation related to acquisition and acquisition-related costs     50       318       1,298       339  
                                 
Non-GAAP operating profit     24,468       24,152       98,668       94,141  
                                 
Depreciation     891       1,115       4,371       3,865  
                                 
Adjusted EBITDA     25,359       25,267       103,039       98,006  

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

    Q4 2024     Q3 2024     Q2 2024     Q1 2024     Q4 2023  
                               
Revenues     134,305       137,025       136,800       134,249       130,914  
Gross profit     62,692       62,809       62,481       60,884       59,370  
Operating income     24,468       25,101       24,836       24,263       24,152  
Adjusted EBITDA     25,359       26,389       25,931       25,360       25,267  
Net income to Sapiens’ shareholders     20,710       21,091       21,041       20,421       20,081  
                                         
Diluted earnings per share     0.37       0.37       0.37       0.36       0.36  

 

Annual Recurring Revenue (“ARR”)

U.S. dollars in thousands 

 

    Three months ended  
    December 31,  
    2024     2023  
Annual Recurring Revenue     175,542       164,840  

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

    Q4 2024     Q3 2024     Q2 2024     Q1 2024     Q4 2023  
                               
North America     56,753       55,755       57,918       55,158       54,882  
Europe     65,903       69,281       66,072       68,727       65,239  
Rest of the World     11,649       11,989       12,810       10,364       10,793  
Total     134,305       137,025       136,800       134,249       130,914  

 

9


 

Non-GAAP Revenue breakdown

U.S. dollars in thousands

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
                         
Software products and re-occurring post-production services (*)     97,336       90,399       390,328       342,156  
Pre-production implementation services (**)     36,969       40,515       152,051       172,648  
Total Revenues     134,305       130,914       542,379       514,804  

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
                         
Software products and re-occurring post-production services (*)     52,356       48,815       208,742       182,154  
Pre-production implementation services (**)     10,336       10,555       40,124       50,831  
Total Gross profit     62,692       59,370       248,866       232,985  

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2024     2023     2024     2023  
                         
Software products and re-occurring post-production services (*)     53.8 %     54.0 %     53.5 %     53.2 %
Pre-production implementation services (**)     28.0 %     26.1 %     26.4 %     29.4 %
Gross Margin     46.7 %     45.4 %     45.9 %     45.3 %

 

(*) Software products and re-occurring post-production services include mainly subscription, term license, maintenance, application maintenance, cloud solutions and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

 

(**) Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

    Q4 2024     Q3 2024     Q2 2024     Q1 2024     Q4 2023  
                               
Cash-flow from operating activities     42,109       13,083       8,545       18,488       38,646  
Increase in capitalized software development costs     (1,759 )     (1,834 )     (1,823 )     (1,717 )     (1,543 )
Capital expenditures     (419 )     (1,125 )     (666 )     (466 )     (421 )
Free cash-flow     39,931       10,124       6,056       16,305       36,682  
                                         
Cash payments attributed to acquisition-related costs(*) (**)     1,238       124       134       751       221  
Adjusted free cash-flow     41,169       10,248       6,190       17,056       36,903  

 

(*) Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as completed or prospective third-party services, such as tax, accounting and legal rendered.

 

10


 


SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

 

    December 31,     December 31,  
    2024     2023  
    (unaudited)     (unaudited)  
             
ASSETS            
             
CURRENT ASSETS            
Cash and cash equivalents     163,690       126,716  
Short-term bank deposit     52,500       75,400  
Trade receivables, net and unbilled receivables     99,603       90,273  
Other receivables and prepaid expenses     19,350       22,514  
Total current assets     335,143       314,903  
                 
LONG-TERM ASSETS                
Property and equipment, net     10,656       12,661  
Severance pay fund     3,208       3,605  
Goodwill and intangible assets, net     302,472       317,352  
Operating lease right-of-use assets     20,746       23,557  
Other long-term assets     19,486       17,546  
Total long-term assets     356,568       374,721  
                 
TOTAL ASSETS     691,711       689,624  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables     8,414       6,291  
Current maturities of Series B Debentures     19,796       19,796  
Accrued expenses and other liabilities     77,390       77,873  
Current maturities of operating lease liabilities     6,440       6,623  
Deferred revenue     37,543       38,541  
Total current liabilities     149,583       149,124  
                 
LONG-TERM LIABILITIES                
Series B Debentures, net of current maturities     19,792       39,543  
Deferred tax liabilities     6,899       10,820  
Other long-term liabilities     10,331       11,538  
Long-term operating lease liabilities     17,719       21,084  
Accrued severance pay     7,758       7,568  
Total long-term liabilities     62,499       90,553  
                 
EQUITY     479,629       449,947  
                 
TOTAL LIABILITIES AND EQUITY     691,711       689,624  

 

11


 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

    For the twelve months ended
December 31,
 
    2024     2023  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     72,320       62,867  
Reconciliation of net income to net cash provided by operating activities:                
Depreciation     4,371       3,865  
Amortization of capitalized software and other intangible assets     15,702       17,574  
Accretion of discount on Series B Debentures     44       64  
Capital loss from sale of property and equipment     19       195  
Stock-based compensation related to options issued to employees     2,952       3,658  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Decrease (increase) in trade receivables, net and unbilled receivables     (12,500 )     3,960  
Decrease in deferred tax liabilities, net     (5,934 )     (3,003 )
Decrease (increase) in other operating assets     5,343       (5,402 )
Increase (decrease) in trade payables     2,126       (3,580 )
Decrease in other operating liabilities     (2,558 )     (8,948 )
Increase (decrease) in deferred revenues     (407 )     7,266  
Increase in accrued severance pay, net     747       909  
Net cash provided by operating activities     82,225       79,425  
                 
Cash flows from investing activities:                
                 
Purchase of property and equipment     (2,879 )     (2,574 )
Proceeds from (investments in) deposits     23,592       (55,499 )
Proceeds from sale of property and equipment     203       48  
Payments for business acquisitions, net of cash acquired     (375 )     (8,060 )
Capitalized software development costs     (7,133 )     (6,518 )
Acquisition of intellectual property     -       (177 )
Net cash provided by (used in) investing activities     13,408       (72,780 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     98       4,809  
Distribution of dividend     (31,823 )     (28,144 )
Repayment of Series B Debenture     (19,796 )     (19,796 )
Acquisition deferred payment     (630 )     -  
Acquisition of non-controlling interests     (4,131 )     (161 )
Dividend to non-controlling interest     -       (47 )
Net cash used in financing activities     (56,282 )     (43,339 )
                 
Effect of exchange rate changes on cash and cash equivalents     (2,377 )     3,125  
                 
Increase (decrease) in cash and cash equivalents     36,974       (33,569 )
Cash and cash equivalents at the beginning of period     126,716       160,285  
                 
Cash and cash equivalents at the end of period     163,690       126,716  

 

12


 

Debentures Covenants

 

As of December 31, 2024, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

§ Target shareholders’ equity (excluding non-controlling interest): above $120 million.

 

§ Actual shareholders’ equity (excluding non-controlling interest) equal to $479.6 million.

 

Covenant 2

 

§ Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.

 

§ Actual ratio of net financial indebtedness to net capitalization equal to (57.93)%.

 

Covenant 3

 

§ Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.

 

§ Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.71).

 

 

13